Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

(ACN, CLNO, SSFN, BGBV, XRIT, RPRX) Stock in Review by

|Includes: Accenture plc (ACN), RPRX, SSFN, XRIT

Stock-PR Reporting



FREE Daily Stock Alerts From




Accenture "high performance business" strategy builds on expertise in consulting, technology and outsourcing to help clients perform at the highest levels so they can create sustainable value for their customers and shareholders. Using our industry knowledge, service-offering expertise and technology capabilities, we identify new business and technology trends and develop solutions to help clients around the world:

Enter new markets.
Increase revenues in existing markets.
Improve operational performance.
Deliver their products and services more effectively and efficiently.

Revenues increase 21% in U.S. dollars and 15% in local currency, to $6.7 billion

EPS up 27%, to $0.93

New bookings are $7.1 billion

Company raises outlook for full-year revenue growth to range of 14% to 15% in local currency and outlook for full-year EPS to range of $3.36 to $3.40

Accenture (NYSE:ACN) reported strong financial results for the third quarter of fiscal 2011, ended May 31, 2011, with net revenues of $6.7 billion, an increase of 21 percent in U.S. dollars and 15 percent in local currency over the same period last year. Diluted earnings per share were $0.93, an increase of $0.20, or 27 percent, over the same period last year.

Operating income was $949 million, an increase of 18 percent over the same period last year, and operating margin was 14.1 percent.

New bookings for the quarter were $7.1 billion, with consulting bookings of $3.7 billion and outsourcing bookings of $3.4 billion.

Pierre Nanterme, Accenture’s chief executive officer, said, “We are very pleased with our third-quarter results. The continued momentum in our business and the focused execution of our growth strategy enabled us to achieve our highest quarterly revenues ever, of more than $6.7 billion. Four of our five operating groups, and all three geographic regions, saw double-digit revenue growth in both U.S. dollars and local currency. We also achieved record quarterly EPS of $0.93, and we have a very strong balance sheet.

“We continue to gain market share, and demand for our services remains robust, as demonstrated by third-quarter bookings in excess of $7 billion. Our focus remains on driving sustainable and profitable growth through technology leadership and industry differentiation, and delivering superior value to our clients and shareholders.”

Business Outlook

Fourth Quarter Fiscal 2011

Accenture expects net revenues for the fourth quarter of fiscal 2011 to be in the range of $6.4 billion to $6.6 billion. This range assumes a foreign-exchange impact of positive 8 percent compared with the fourth quarter of fiscal 2010.

Full Fiscal Year 2011

Accenture’s business outlook for the full 2011 fiscal year now assumes a foreign-exchange impact of positive 3 percent compared with fiscal 2010. The annual business outlook provided in the company’s second-quarter fiscal 2011 earnings announcement in March assumed a foreign-exchange impact of positive 2 percent for the full fiscal year.

For fiscal 2011, the company has raised its outlook for net revenue growth to the range of 14 percent to 15 percent in local currency from its previous range of 11 percent to 14 percent in local currency. The company has also raised its outlook for annual diluted EPS to the range of $3.36 to $3.40 from its previous range of $3.22 to $3.30.

Accenture continues to expect operating margin for the full fiscal year to be in the range of 13.6 percent to 13.7 percent.

The company now expects operating cash flow to be in the range of $2.9 billion to $3.1 billion; now expects property and equipment additions to be $400 million; and now expects free cash flow to be in the range of $2.5 billion to $2.7 billion. The company now expects its annual effective tax rate to be in the range of 27 percent to 28 percent.

Accenture now expects new bookings to be at the upper end of its previously guided range of $25 billion to $28 billion for the full fiscal year.

Its home page is

**************************************************** Cleantech Transit Inc. (OTCPK:CLNO)

Cleantech Transit Inc.
was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy ( This project can generate shareholder returns as well benefit the Company's manufacturing clients worldwide.

Cleantech Transit, Inc. is pleased to announce it has completed an agreement whereby it can earn a larger ownership percentage in the 500 KW bio mass Merced Project than previously announced.

Cleantech can now earn in up to 40% of the Merced Project up from the original 25% the Company announced. The 40% ownership stake will be based on the total cost incurred to the Project to date, in addition Cleantech can invest the in the Series B shares of Phoenix Energy equal to or greater to the direct investment made in 500 KW project.

Biomass is considered to be one of the key renewable resources of the future at both small- and large-scale levels. It already supplies 14 % of the world's primary energy consumption. But for three quarters of the world's population living in developing countries biomass is the most important source of energy. With increases in population and per capita demand, and depletion of fossil-fuel resources, the demand for biomass is expected to increase rapidly in developing countries. On average, biomass produces 38 % of the primary energy in developing countries (90 % in some countries). Biomass is likely to remain an important global source in developing countries well into the next century. Even in developed countries, biomass is being increasingly used.

Please visit Cleantech Transit, Inc. website


Stewardship Financial Corporation (NASDAQ:SSFN), parent company of Atlantic Stewardship Bank, has declared a $0.05 per share cash dividend. Common stockholders of record as of July 15, 2011 will be paid the dividend on August 1, 2011.

Stewardship Financial Corporation operates as the holding company for Atlantic Stewardship Bank that provides commercial and retail banking services to small and medium sized businesses and individuals in Bergen, Morris, and Passaic counties, New Jersey.


bgbv_logo_200x72 Blue Gold Beverages, Inc. (OTC:BGBV)

Blue Gold Beverages, Inc
. is a leading high end producer of private label water and specialty beverages in North America. Some of our products include all natural sodas, teas, non-alcoholic wine coolers and energy drinks. Blue Gold Beverages head office situated in Montreal, Quebec, Canada.

Drinking water helps you lose weight because it flushes down the by-products of fat breakdown. Drinking water reduces hunger; it's an effective appetite suppressant so you'll eat less. Plus, water has zero calories. You'll look younger when your skin is properly hydrated. Water helps to replenish skin tissues, moisturizes skin and increase skin elasticity.

Blue Gold Beverages, Inc. (OTC:BGBV) is pleased to announce it s wholly owned subsidiary EPIC Nutrition, Inc. has launched Goodnight™ 2.5 fl oz sleep shots. The product contains a proprietary blend of active ingredients and is one of the early entrants in the liquid delivery system of sleep aids.

Goodnight's proprietary formula promotes slow-wave "DELTA" or deep sleep. "A Goodnight's sleep is often the best way to help cope with stress, solve problems and recover from illness." continues Mr. Movic. "Goodnight will be supported by an interactive website, QR reader capabilities and social networking sites Twitter and Face book providing updates promoting health sleeping habits, product promotions and discounts."

Statistics from Market data Enterprises, Inc. (, leading independent market research published reports 58% or more than 175 million of all Americans are estimated to experience insomnia symptoms or sleep disorders. Market data estimates that the U.S. sleep market was worth US$ 23.7 billion in 2007.

For more information BGBV, please visit:


X-Rite, Incorporated (NASDAQ:XRIT), the world leader in color management, measurement and communication technologies, announced the immediate availability of i1Display Pro and ColorMunki Display, two all-new technologically advanced hardware and software solutions for color calibration and profiling of displays, laptops and projectors.

X-Rite, Incorporated, a technology company, develops a range of color management systems primarily in the United States, Europe, and Asia. The company offers various management solutions comprising hardware, software, and services.


Repros Therapeutics Inc.(NYSE:R) (Nasdaq:RPRX) announced it has commenced enrolling subjects in the 9 mg cohort in the Company's low dose study of Proellex(R) following a safety review of data from women that have completed 8 weeks of treatment at a 6 mg dose. No signals of liver toxicity have been detected to date in subjects who were dosed in the 6 mg group. Proellex(R) is an oral therapy in development for the treatment of uterine fibroids and endometriosis. Large Phase III clinical studies exhibited severe liver toxicity in a small percentage of subjects that were exposed to a 50 mg dose. As a result of these observations, the program was placed on full clinical hold until the phenomenon could be better understood. After an analysis of all the subjects that had been exposed to Proellex(R), Repros petitioned the Food and Drug Administration ("FDA") to allow the Company to conduct a low dose trial to assess impact on the liver and signals of efficacy. In the summer of 2010, the FDA moved Proellex(R) to partial hold status to allow for the low dose study.

Repros Therapeutics, Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for the treatment of male and female reproductive disorders. Repros Therapeutics, Inc. was founded in 1987 and is based in The Woodlands, Texas.



Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) anticipates receiving 5,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services for Cleantech Transit, Inc. (OTCPK:CLNO). Crown Equity Holdings Inc. (OTCPK:CRWE) has received seven thousand five hundred dollars ($7,500) in cash from a third party (9186 2780 Quebec Inc) for 1 week of media advertisement services for Blue Gold Beverages, Inc. (OTC:BGBV).

Sign Up For Free Stock Alerts At